Home > Healthcare > Medical Devices > Diagnostic Devices > Clinical Chemistry Analyzers Market

Clinical Chemistry Analyzers Market Trends

Report ID: GMI8435
Published Date: Mar 2024
Report Format: PDF

Download Free Sample

Clinical Chemistry Analyzers Market Trends

Growing adoption of point of care testing (POCT) in clinical chemistry analyzers signifies a paradigm shift in healthcare delivery, bringing diagnostic testing closer to the patient, improving access to timely and accurate diagnostic information, and ultimately revolutionizing the way healthcare is delivered and managed.

In chronic disease management, such as diabetes or heart failure, point of care testing enables healthcare providers to monitor patients' health status more closely and adjust treatment plans as needed.
Furthermore, POCT allows for immediate testing and results delivery, eliminating the need for sample transportation to centralized laboratories and reducing turnaround time.
Moreover, devices in POCT often include decision support tools and algorithms to assist healthcare providers in interpreting test results and making informed clinical decisions. These decision support features can help optimize treatment strategies, reduce diagnostic errors, and improve patient outcomes.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global clinical chemistry analyzers market was valued at USD 15.2 billion in 2023 and is estimated to record a CAGR of 4.1% between 2024 and 2032, driven by the increasing prevalence of chronic disorders and lifestyle diseases.

The centralized segment accounted for around USD 6.6 billion revenue size in 2023, as it offers numerous advantages in terms of efficiency, cost-effectiveness, space-saving, standardization, quality control, integration, and scalability.

North America clinical chemistry analyzers industry accounted for USD 6.5 billion revenue in 2023, attributed to growing prevalence of chronic disorders such cardiovascular diseases, diabetes, and cancer.

Abbott Laboratories, Danaher Corporation, EKF Diagnostics, F.Hoffmann-La Roche Ltd., Hitachi Ltd., HORIBA Ltd., Ortho Clinical Diagnostics, QuidelOrtho Corporation, Siemens Healthineers AG, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Sysmex Corporation, and Thermo Fisher Scientific Inc.